-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 CchnkcZR/nMu0rsszuGVmSBsbh9qv8wrrmlnlh36q7aY++MsJA77xQPJBTgrZljS
 s+bBoufb0VcGNlQ6yJB7vw==

<SEC-DOCUMENT>0001127855-04-000789.txt : 20041228
<SEC-HEADER>0001127855-04-000789.hdr.sgml : 20041228
<ACCEPTANCE-DATETIME>20041228112725
ACCESSION NUMBER:		0001127855-04-000789
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20041231
FILED AS OF DATE:		20041228
DATE AS OF CHANGE:		20041228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SINOVAC BIOTECH LTD
		CENTRAL INDEX KEY:			0001084201
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			B9
		FISCAL YEAR END:			0430

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-32371
		FILM NUMBER:		041227672

	BUSINESS ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085
		BUSINESS PHONE:		86-10-82890088

	MAIL ADDRESS:	
		STREET 1:		39 SHANGDI XI ROAD
		STREET 2:		HAIDIAN DISTRICT
		CITY:			BEIJING
		STATE:			F4
		ZIP:			100085

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NET FORCE SYSTEMS INC
		DATE OF NAME CHANGE:	19991110
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>sinovac6k123104.txt
<DESCRIPTION>SINOVAC BIOTECH LTD. 6K, 12.31.04
<TEXT>






                                  UNITED STATES
                       SECURITIES AND EXCHANGE COMMISSION
                              Washington, DC 20549

                                    FORM 6-K
                                    --------

       REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
                    UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of December, 2004.

Commission File Number: 0-29031

                              SINOVAC BIOTECH LTD.
                              --------------------
                       (Name of Registrant in its charter)

                               ANTIGUA and BARBUDA
                               -------------------
         (State or other jurisdiction of incorporation or organization)

                               39 Shangdi Xi Road
                            Haidian District, Beijing
                                  China 100085
                            -------------------------
              (Address of principal executive offices and zip code)

                               Tel: 86-10-82890088
                               Fax: 86-10-62966910
                               -------------------
                      (Issuer's telephone and fax numbers)

Indicate by check mark whether the registrant  files or will file annual reports
under cover Form 20-F or Form 40-F

                           Form 20-F  X      Form 40-F
                                    -----             -----

Indicate by check mark whether the  registrant  by  furnishing  the  information
contained  in this  Form is  also  thereby  furnishing  the  information  to the
Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

                           Yes               No  X
                              -----            -----

If "Yes" is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b):  82-
                                    ------



<PAGE>






INDEX
- -----

Item
- ----

1.   Financial Advisory Agreement with Credit Suisse Advisory Partners AG

2.   Press Release dated December 21, 2004 - Exhibit 99.1


Item 1.  Financial Advisory Agreement with Credit Suisse Advisory Partners AG
- -----------------------------------------------------------------------------

Effective December 14, 2004, the Board of Directors of Sinovac Biotech Ltd. (the
"Company")  approved the Financial  Advisory  Agreement entered into between the
Company and Credit Suisse Advisory Partners AG ("Credit Suisse"), a 100% - owned
subsidiary of Credit Suisse Group headquartered in Zurich, Switzerland,  whereby
Credit  Suisse will act as the Company's  exclusive  financial  advisor.  Credit
Suisse Group is a leading global financial services company.

Item 2.  Press Release dated December 21, 2004 - 99.1
- -----------------------------------------------------


                                   SIGNATURES
                                   ----------

Pursuant  to the  requirements  of the  Securities  Exchange  Act of  1934,  the
registrant  has duly  caused  this  report  to be  signed  on its  behalf by the
undersigned, thereunto duly authorized.


                                                SINOVAC BIOTECH LTD.
                                                --------------------

Date:  December 28, 2004                        By:      /s/ Weidong Yin
                                                    ----------------------------
                                                    Weidong Yin, President, CEO
                                                    and a Director




</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>sinovacexh99_1.txt
<DESCRIPTION>SINOVAC BIOTECH LTD. 6K, PRESS RELEASE, 12.21.04
<TEXT>






EXHIBIT 99.1
- ------------


                              SINOVAC BIOTECH LTD.
                              --------------------
                    ENTERS INTO FINANCIAL ADVISORY AGREEMENT
                    ----------------------------------------
                    WITH CREDIT SUISSE ADVISORY PARTNERS A.G.
                    -----------------------------------------


BEIJING,  December 21, 2004 - Sinovac Biotech Ltd.  ("Sinovac")  ("the Company")
(AMEX: SVA) is pleased to announce that it has entered into a Financial Advisory
Agreement with Credit Suisse  Advisory  Partners AG, a 100%-owned  subsidiary of
Credit Suisse Group headquartered in Zurich, Switzerland,  whereby Credit Suisse
Advisory Partners will act as the Company's exclusive financial advisor.  Credit
Suisse Group is a leading global financial services company.

About Sinovac Biotech Ltd.
- --------------------------

Sinovac    Biotech   Ltd.    specializes    in   the   research,    development,
commercialization,  and sales of human vaccines for infectious illnesses such as
hepatitis A and hepatitis B, influenza, "SARS", and avian flu. Sinovac is one of
the leading emerging biotechnology companies in China.

Sinovac has three  vaccines  that have  completed  all three  phases of clinical
trials - Hepatitis A, Hepatitis A&B combined, and influenza (flu). The Hepatitis
A vaccine,  Healive(TM),  is currently experiencing strong sales growth in China
and  applications  have been filed for its sale in nine other countries to date.
Sinovac's  Hepatitis A&B combined  vaccine,  Bilive(TM),  is expected to receive
approval to commence sales in China soon and to achieve  similar sales growth to
Healive(TM).  The flu vaccine completed  clinical trials in April 2004 and a New
Drug  Application  has been  filed  with the SFDA  (Chinese  FDA).  Approval  of
Sinovac's  flu vaccine is expected  in 2005 upon  completion  of the flu vaccine
production  line.  Since  demand for a safe and  effective  flu vaccine in China
greatly outstrips supply,  sales are expected to escalate rapidly.  Furthermore,
since individuals are vaccinated against the flu on an annual basis, demand will
remain high every year.

Sinovac is  currently  the only company in the world to be  conducting  clinical
trials for a vaccine to prevent SARS.  The Company is also  developing a vaccine
targeting  avian flu in  partnership  with the China  Center of Disease  Control
(CDC).

For further  information  please refer to the Company's  filings with the SEC on
EDGAR or refer to Sinovac's website at www.sinovac.com.
                                       ---------------

If you would like to receive  regular  updates on Sinovac please send your email
request to info@sinovac.com.
           ----------------

Contact:  Investor Relations at (888) 888-8312 or 1 604 684-5990 from outside of
North America or info@sinovac.com
                 ----------------




THIS NEWS RELEASE MAY INCLUDE  FORWARD-LOOKING  STATEMENTS WITHIN THE MEANING OF
SECTION 27A OF THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED, AND SECTION
21E OF THE UNITED STATES  SECURITIES AND EXCHANGE ACT OF 1934, AS AMENDED,  WITH
RESPECT  TO  ACHIEVING  CORPORATE  OBJECTIVES,   DEVELOPING  ADDITIONAL  PROJECT
INTERESTS,   SINOVAC'S   ANALYSIS  OF   OPPORTUNITIES  IN  THE  ACQUISITION  AND
DEVELOPMENT  OF VARIOUS  PROJECT  INTERESTS  AND CERTAIN  OTHER  MATTERS.  THESE
STATEMENTS  ARE MADE UNDER THE "SAFE  HARBOR"  PROVISIONS  OF THE UNITED  STATES
PRIVATE  SECURITIES  LITIGATION  REFORM  ACT  OF  1995  AND  INVOLVE  RISKS  AND
UNCERTAINTIES  WHICH COULD CAUSE ACTUAL RESULTS TO DIFFER  MATERIALLY FROM THOSE
IN THE FORWARD-LOOKING STATEMENTS CONTAINED HEREIN.





</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
